Evidence map›Paper›PMID 40454888›Full record

ArticlemBio2025

Structural basis for varying drug resistance of SARS-CoV-2 M

Morgan A Esler, Ke Shi, Joseph A Rollie, Renee Delgado, Jyoti Vishwakarma, Agnieszka Dabrowska, Janani Prahlad, Seyed Arad Moghadasi, Reuben S Harris, Hideki Aihara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Slowly exchanging bound states of SARS-CoV-2 3CLStructural dynamics (Melville, N.Y.) · 2026
    Article
  3. Next-generation inhibitors of SARS-CoV-2 MNature communications · 2026
    Article
  4. Article
  5. A Novel Fluorescence Polarization Binding Assay for the Main Protease (MACS pharmacology & translational science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Morgan A EslerDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Ke ShiDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Joseph A RollieDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Renee DelgadoDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Jyoti VishwakarmaDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Agnieszka DabrowskaDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Janani PrahladDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Seyed Arad MoghadasiDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Reuben S HarrisDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-9034-9112
Hideki AiharaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0001-7508-6230

Funding

Project 5: Pandemic Virus Helicase InhibitorsU19AI171954 · NIAID · UNIVERSITY OF MINNESOTA · PI Donghoon Chung · 2022 to 2026
$100.9M
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Vivian Stojanoff · 2019 to 2026
$38.6M
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI STEVEN E EALICK · 2018 to 2026
$34.2M
Structural studies of viral replication and invasionR35GM118047 · NIGMS · UNIVERSITY OF MINNESOTA · PI Hideki Aihara · 2016 to 2026
$6.3M
Pixel Array Detector for X-ray CrystallographyS10RR029205 · NCRR · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2010 to 2010
$1.8M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19-AI171954HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35-GM118047NCRR NIH HHS S10 RR029205NIAID NIH HHS U19 AI171954NIGMS NIH HHS P30 GM124165NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R35 GM118047
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesDrug Resistance, ViralSARS-CoV-2COVID-19COVID-19 Drug TreatmentCrystallography, X-RayHumansLactamsLeucineModels, MolecularMutationNitrilesProlineProtein Conformation3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesLactamsLeucinenirmatrelvirNitrilesProlineantiviral drugBofutrelvircrystal structuredrug resistance mechanismsEnsitrelvirNirmatrelvirSARS-CoV-2viral protease

Identifiers

PMID40454888
PMCPMC12239574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.